Blue versus white light for transurethral resection of non-muscle invasive bladder cancer - PubMed
5 hours ago
- #Blue Light Therapy
- #TURBT
- #Bladder Cancer
- Blue light TURBT may reduce disease recurrence in intermediate- and high-risk NMIBC patients compared to white light TURBT, with hazard ratios (HR) indicating lower recurrence rates.
- It may also reduce disease progression in high-risk NMIBC patients, though effects on low- and intermediate-risk groups are minimal or negligible.
- Serious surgical complications, death from bladder cancer, and adverse events show little to no difference between blue light and white light TURBT, based on low-certainty evidence.
- The update includes 17 randomized controlled trials with 4890 participants, synthesizing evidence until March 2026, and uses GRADE for certainty assessment.
- Authors conclude that blue light TURBT benefits vary by baseline risk, with low evidence certainty due to study limitations, inconsistency, and imprecision, suggesting future research may alter findings.